These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 12534363)
1. A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Céraline J; Erdmann E; Erbs P; Deslandres-Cruchant M; Jacqmin D; Duclos B; Klein-Soyer C; Dufour P; Bergerat JP Eur J Endocrinol; 2003 Jan; 148(1):99-110. PubMed ID: 12534363 [TBL] [Abstract][Full Text] [Related]
2. Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Céraline J; Cruchant MD; Erdmann E; Erbs P; Kurtz JE; Duclos B; Jacqmin D; Chopin D; Bergerat JP Int J Cancer; 2004 Jan; 108(1):152-7. PubMed ID: 14618630 [TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Tan J; Sharief Y; Hamil KG; Gregory CW; Zang DY; Sar M; Gumerlock PH; deVere White RW; Pretlow TG; Harris SE; Wilson EM; Mohler JL; French FS Mol Endocrinol; 1997 Apr; 11(4):450-9. PubMed ID: 9092797 [TBL] [Abstract][Full Text] [Related]
8. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Wetherill YB; Fisher NL; Staubach A; Danielsen M; de Vere White RW; Knudsen KE Cancer Res; 2005 Jan; 65(1):54-65. PubMed ID: 15665279 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens. Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455 [TBL] [Abstract][Full Text] [Related]
10. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. Kokontis J; Ito K; Hiipakka RA; Liao S Receptor; 1991; 1(4):271-9. PubMed ID: 1668832 [TBL] [Abstract][Full Text] [Related]
11. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Culig Z; Hobisch A; Cronauer MV; Cato AC; Hittmair A; Radmayr C; Eberle J; Bartsch G; Klocker H Mol Endocrinol; 1993 Dec; 7(12):1541-50. PubMed ID: 8145761 [TBL] [Abstract][Full Text] [Related]
12. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Attardi BJ; Burgenson J; Hild SA; Reel JR Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132 [TBL] [Abstract][Full Text] [Related]
13. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. Matias PM; Carrondo MA; Coelho R; Thomaz M; Zhao XY; Wegg A; Crusius K; Egner U; Donner P J Med Chem; 2002 Mar; 45(7):1439-46. PubMed ID: 11906285 [TBL] [Abstract][Full Text] [Related]
14. The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Comuzzi B; Lambrinidis L; Rogatsch H; Godoy-Tundidor S; Knezevic N; Krhen I; Marekovic Z; Bartsch G; Klocker H; Hobisch A; Culig Z Am J Pathol; 2003 Jan; 162(1):233-41. PubMed ID: 12507906 [TBL] [Abstract][Full Text] [Related]
16. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. Taplin ME; Rajeshkumar B; Halabi S; Werner CP; Woda BA; Picus J; Stadler W; Hayes DF; Kantoff PW; Vogelzang NJ; Small EJ; J Clin Oncol; 2003 Jul; 21(14):2673-8. PubMed ID: 12860943 [TBL] [Abstract][Full Text] [Related]
17. Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. Han G; Foster BA; Mistry S; Buchanan G; Harris JM; Tilley WD; Greenberg NM J Biol Chem; 2001 Apr; 276(14):11204-13. PubMed ID: 11063747 [TBL] [Abstract][Full Text] [Related]
18. Syringaresinol as a novel androgen receptor antagonist against wild and mutant androgen receptors for the treatment of castration-resistant prostate cancer: molecular docking, Selvaraj D; Muthu S; Kotha S; Siddamsetty RS; Andavar S; Jayaraman S J Biomol Struct Dyn; 2021 Feb; 39(2):621-634. PubMed ID: 31928160 [TBL] [Abstract][Full Text] [Related]
19. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
20. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells. Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]